Irides: Weekly global patent litigation update, Richard Pinckney, Claire Phipps
The EU Parliament proposed reforms to the IPRED to ensure proportionality in patent remedies, addressing concerns about permanent injunctions. The UPC's Milan Division ruled in favor of ASUS in a FRAND defense case against Ericsson, while the Düsseldorf Division set high standards for prior public use challenges. GSK won a cross-border injunction against Pfizer and BioNTech over Comirnaty vaccines, with the UPC finding GSK's patent valid and infringed.
How this was made

The 30-second read
Why it matters
Legal outcomes may reshape IP enforcement strategies and affect valuation of companies involved in SEP and vaccine patents.
Market read
While the rulings are legally significant, they offer limited immediate trading opportunities.
What to watch
Potential for settlement negotiations that could mitigate damage costs; the decisions may set precedents that benefit future licensing revenue.
Background
The article summarizes recent UPC and national court decisions affecting major tech and pharma companies.
Ticker impact
Ericsson's FRAND defence was rejected by the UPC Milan Local Division, confirming liability for damages.
likely pressure as the market prices in potential damages for Ericsson.
Legal loss may affect investor sentiment and future licensing negotiations.
GSK secured a cross‑border injunction against Pfizer and BioNTech over its RNA‑vaccine liposome patent.
potential upside as the ruling strengthens GSK's patent portfolio.
The decision may improve GSK's leverage in vaccine‑related licensing.
Pfizer was found infringing GSK's liposome patent for the Comirnaty vaccine.
likely pressure as investors assess liability exposure.
Infringement could lead to royalty payments or settlement costs.
BioNTech, co‑developer of Comirnaty, was also found infringing GSK's patent.
potential downside as market prices in possible damages.
The ruling may affect BioNTech's profit margins and licensing negotiations.
Market effects
Highlights ongoing uncertainty in the European patent litigation environment, affecting tech and pharma licensing risk assessments.
Primarily EU‑centric; limited immediate effect on broader US markets.
Modest, as the cases involve major multinational firms and could influence future cross‑border IP strategies.
Counterpoint
Investors may view the rulings as isolated legal outcomes with limited long‑term financial impact.
Key entities
- CompanyEricsson
Swedish telecom equipment maker involved in FRAND defence case.
- CompanyASUSTeK
Taiwanese computer manufacturer that successfully raised a FRAND defence.
- CompanyGSK
British pharma firm that secured an injunction over its RNA‑vaccine patent.
- CompanyPfizer
US pharma company found infringing GSK's patent.
- CompanyBioNTech
German biotech co‑developer of Comirnaty, also found infringing.



